Overview

Sequential AG and mFOLFOX Combined With Serplulimab Injection and Bevacizumab Injection in Untreated Advanced Pancreatic Cancer

Status:
RECRUITING

Trial end date:
2025-12-31

Target enrollment:

Participant gender:

Summary

It is a single arm, open-label, multicenter, phase II cinical trial to evaluate the efficacy and safety of the Sequential AG and mFOLFOX in Combination With Serplulimab Injection and Bevacizumab Injection in first-line treatment of patients with Advanced or Metastatic Pancreatic Cancer.

Phase:

PHASE2

Details

Lead Sponsor:

Zhejiang Cancer Hospital

Treatments:

Bevacizumab